For many years, experts have been talking about the importance of studying hemophilia inhibitors. Thanks to technology that helps understand genes and mutations, health care providers and scientists now know more about the risks of developing an inhibitor based on the types of genetic mutations that cause hemophilia. Researchers are also exploring how treatment, certain genetic mutations causing hemophilia, and factors involved in a person’s immune system can work together to increase risk for an inhibitor.
Participating in research is an individual decision, but it can lead to contributing to the development of improved treatment and care for people with bleeding disorders. To learn more about clinical trials, giving consent, and what to expect, when you become part of a study check out NBDF’s Clinical Trial Essentials.